Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88
AI-Enabled Firm Raised $464.7m From IPO, Private Placement
Executive Summary
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
You may also be interested in...
MoonLake Takes SPAC Route To Challenge Novartis's Cosentyx
MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.
IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors